SIMILAR EFFICACY OF EGFR TYROSINE KINASE INHIBITORS REGARDLESS OF TREATMENT SEQUENCE FOR THE PATIENTS WITH EGFR MUTATION-POSITIVE PULMONARY ADENOCARCINOMA

被引：0

作者：

Koo, Dong Hoe ^{[1
]}

Kim, Kyu-Pyo ^{[1
]}

Choi, Chang-Min ^{[1
]}

Lee, Dae-Ho ^{[1
]}

Lee, Jae Cheol ^{[1
]}

Lee, Jung-Shin ^{[1
]}

Jang, Se Jin ^{[1
]}

Kim, Sang-We ^{[1
]}

机构：

[1] Asan Med Ctr, Seoul, South Korea

来源：

JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期

关键词：

Treatment sequence; Adenocarcinoma; EGFR mutation; Tyrosine kinase inhibitor;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S409 / S410

页数：2

共 50 条

[1] EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors
Yang, Jiyoul
Lee, Ok-Jun
Son, Seung-Myoung
Woo, Chang Gok
Jeong, Yusook
Yang, Yaewon
Kwon, Jihyun
Lee, Ki Hyeong
Han, Hye Sook
CANCER RESEARCH AND TREATMENT, 2018, 50 (03): : 908 - 916
[2] Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation-positive Lung Cancer
Ogimoto, Tatsuya
Ozasa, Hiroaki
Tsuji, Takahiro
Funazo, Tomoko
Yamazoe, Masatoshi
Hashimoto, Kentaro
Yoshida, Hiroshi
Hosoya, Kazutaka
Ajimizu, Hitomi
Nomizo, Takashi
Yoshida, Hironori
Hamaji, Masatsugu
Menju, Toshi
Yoshizawa, Akihiko
Date, Hiroshi
Hirai, Toyohiro
MOLECULAR CANCER THERAPEUTICS, 2024, 23 (04) : 564 - 576
[3] Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors
Liao, Bin-Chi
Bai, Ya-Ying
Lee, Jih-Hsiang
Lin, Chia-Chi
Lin, Shu-Yung
Lee, Yee-Fan
Ho, Chao-Chi
Shih, Jin-Yuan
Chang, Yeun-Chung
Yu, Chong-Jen
Yang, James Chih-Hsin
Yang, Pan-Chyr
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2018, 117 (04) : 326 - 331
[4] Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma
Eun Young Kim
Arum Kim
Gaeun Lee
Hangsuck Lee
Yoon Soo Chang
BMC Cancer, 18
[5] Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma
Kim, Eun Young
Kim, Arum
Lee, Gaeun
Lee, Hangsuck
Chang, Yoon Soo
BMC CANCER, 2018, 18
[6] EGFR Tyrosine Kinase Inhibitor and Chemotherapy in EGFR Mutation-Positive Non-Small Cell Lung Cancer
Nishino, Kazumi
Kimura, Madoka
Inoue, Takako
Uchida, Junji
Kumagai, Toru
Imamura, Fumio
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S526 - S526
[7] The Frequency of EGFR Mutation in Lung Adenocarcinoma and the Efficacy of Tyrosine Kinase Inhibitor Therapy in a Hungarian Cohort of Patients
Sarosi, Veronika
Baliko, Zoltan
Smuk, Gabor
Laszlo, Terezia
Szabo, Mariann
Ruzsics, Istvan
Mezosi, Emese
PATHOLOGY & ONCOLOGY RESEARCH, 2016, 22 (04) : 755 - 761
[8] Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers
Offin, Michael
Rizvi, Hira
Tenet, Megan
Ni, Andy
Sanchez-Vega, Francisco
Li, Bob T.
Drilon, Alexander
Kris, Mark G.
Rudin, Charles M.
Schultz, Nikolaus
Arcila, Maria E.
Ladanyi, Marc
Riely, Gregory J.
Yu, Helena
Hellmann, Matthew D.
CLINICAL CANCER RESEARCH, 2019, 25 (03) : 1063 - 1069
[9] Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors
Hirsh, Vera
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
[10] Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer
Su, Po-Lan
Wu, Yi-Lin
Chang, Wei-Yuan
Ho, Chung-Liang
Tseng, Yau-Lin
Lai, Wu-Wei
Su, Wu-Chou
Lin, Chien-Chung
Yang, Szu-Chun
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10

← 1 2 3 4 5 →